Literature DB >> 19086162

Proteinase-activated receptor 2 (PAR-2) in gastrointestinal and pancreatic pathophysiology, inflammation and neoplasia.

Kjetil Søreide1.   

Abstract

Of all the body systems, the gastrointestinal (GI) tract is the most exposed to proteinases. Proteolytic activity must thus be tightly regulated in the face of diverse environmental challenges, because unrestrained or excessive proteolysis leads to pathological GI conditions. The protease-activated receptor-2 (PAR-2) is expressed in numerous cell types within the GI tract, suggesting both multiple functions and numerous modes of receptor activation. Although best known as a pancreatic digestive enzyme, trypsin has also been found in other tissues and various cancers. Of interest, trypsin and PAR-2 act together in an autocrine loop that promotes proliferation, invasion and metastasis in neoplasia through various mechanisms. Trypsin and PAR-2 seem to act both directly and indirectly through activation of other proteinase cascades, including metalloproteinases. PAR-2 activation can participate in inflammatory reactions, be protective to mucosal surfaces, send or inhibit nociceptive messages, modify gut motility or secretory functions, and stimulate cell proliferation and motility. Several studies point to a role for the PARs in disease processes of the GI tract and pancreas ranging from inflammatory bowel disease, symptoms associated with irritable bowel syndrome, pain in pancreatitis, development of colon and other GI cancers, and even infectious colitis. Proteinases should not only be considered from the traditional view as digestive or degradative enzymes in the gut, but additionally as signalling molecules that actively participate in the spectrum of physiology and diseased states of the GI tract.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19086162     DOI: 10.1080/00365520801942141

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  9 in total

Review 1.  Gastroesophageal reflux disease--from reflux episodes to mucosal inflammation.

Authors:  Arne Kandulski; Peter Malfertheiner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-22       Impact factor: 46.802

Review 2.  Gut microbes, diet, and cancer.

Authors:  Meredith A J Hullar; Andrea N Burnett-Hartman; Johanna W Lampe
Journal:  Cancer Treat Res       Date:  2014

3.  Pharmacological inhibition of PAR2 with the pepducin P2pal-18S protects mice against acute experimental biliary pancreatitis.

Authors:  E S Michael; A Kuliopulos; L Covic; M L Steer; G Perides
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-12-28       Impact factor: 4.052

4.  Potent agonists of the protease activated receptor 2 (PAR2).

Authors:  Scott Boitano; Andrea N Flynn; Stephanie M Schulz; Justin Hoffman; Theodore J Price; Josef Vagner
Journal:  J Med Chem       Date:  2011-02-04       Impact factor: 7.446

5.  Protease-activated receptor 2 activation is sufficient to induce the transition to a chronic pain state.

Authors:  Dipti V Tillu; Shayne N Hassler; Carolina C Burgos-Vega; Tammie L Quinn; Robert E Sorge; Gregory Dussor; Scott Boitano; Josef Vagner; Theodore J Price
Journal:  Pain       Date:  2015-05       Impact factor: 7.926

6.  Elevated fecal peptidase D at onset of colitis in Galphai2-/- mice, a mouse model of IBD.

Authors:  Daniel Bergemalm; Robert Kruse; Maria Sapnara; Jonas Halfvarson; Elisabeth Hultgren Hörnquist
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

Review 7.  Gut microbes as future therapeutics in treating inflammatory and infectious diseases: Lessons from recent findings.

Authors:  Suprabhat Mukherjee; Nikhilesh Joardar; Subhasree Sengupta; Santi P Sinha Babu
Journal:  J Nutr Biochem       Date:  2018-08-16       Impact factor: 6.048

8.  High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer.

Authors:  A Gaber; M Johansson; U-H Stenman; K Hotakainen; F Pontén; B Glimelius; A Bjartell; K Jirström; H Birgisson
Journal:  Br J Cancer       Date:  2009-04-21       Impact factor: 7.640

Review 9.  Is There a Trojan Horse to Aggressive Pancreatic Cancer Biology? A Review of the Trypsin-PAR2 Axis to Proliferation, Early Invasion, and Metastasis.

Authors:  Kjetil Søreide; Marcus Roalsø; Jan Rune Aunan
Journal:  J Pancreat Cancer       Date:  2020-02-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.